NAMS
Price
$17.47
Change
+$0.20 (+1.16%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
1.9B
13 days until earnings call
QURE
Price
$14.25
Change
-$0.14 (-0.97%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
778.17M
19 days until earnings call
Ad is loading...

NAMS vs QURE

Header iconNAMS vs QURE Comparison
Open Charts NAMS vs QUREBanner chart's image
NewAmsterdam Pharma
Price$17.47
Change+$0.20 (+1.16%)
Volume$28.46K
Capitalization1.9B
uniQure
Price$14.25
Change-$0.14 (-0.97%)
Volume$15.36K
Capitalization778.17M
NAMS vs QURE Comparison Chart
Loading...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NAMS vs. QURE commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Buy and QURE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (NAMS: $17.27 vs. QURE: $14.39)
Brand notoriety: NAMS and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 32% vs. QURE: 98%
Market capitalization -- NAMS: $1.9B vs. QURE: $778.17M
NAMS [@Biotechnology] is valued at $1.9B. QURE’s [@Biotechnology] market capitalization is $778.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, both NAMS and QURE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 6 TA indicator(s) are bullish while QURE’s TA Score has 4 bullish TA indicator(s).

  • NAMS’s TA Score: 6 bullish, 4 bearish.
  • QURE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than QURE.

Price Growth

NAMS (@Biotechnology) experienced а +7.74% price change this week, while QURE (@Biotechnology) price change was +53.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was -6.02%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

NAMS is expected to report earnings on Aug 12, 2025.

QURE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($1.9B) has a higher market cap than QURE($778M). QURE YTD gains are higher at: -18.516 vs. NAMS (-32.802). QURE has higher annual earnings (EBITDA): -160.74M vs. NAMS (-241.49M). NAMS has more cash in the bank: 834M vs. QURE (368M). NAMS has less debt than QURE: NAMS (448K) vs QURE (66.1M). NAMS has higher revenues than QURE: NAMS (45.6M) vs QURE (27.1M).
NAMSQURENAMS / QURE
Capitalization1.9B778M244%
EBITDA-241.49M-160.74M150%
Gain YTD-32.802-18.516177%
P/E RatioN/AN/A-
Revenue45.6M27.1M168%
Total Cash834M368M227%
Total Debt448K66.1M1%
FUNDAMENTALS RATINGS
QURE: Fundamental Ratings
QURE
OUTLOOK RATING
1..100
25
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
88
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NAMSQURE
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
38%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 9 days ago
70%
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
View a ticker or compare two or three
Ad is loading...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRIEX12.69N/A
N/A
Meridian Hedged Equity Investor
FHJUX38.97N/A
N/A
Fidelity Advisor Europe A
TRZRX14.43N/A
N/A
T. Rowe Price Real Assets Z
SGACX17.89N/A
N/A
Virtus SGA Global Growth C
CSGYX24.37N/A
N/A
Columbia Small Cap Growth Inst3

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+2.86%
QURE - NAMS
52%
Loosely correlated
N/A
CMRX - NAMS
49%
Loosely correlated
N/A
CRDF - NAMS
39%
Loosely correlated
-4.10%
AUPH - NAMS
34%
Loosely correlated
+2.41%
CGON - NAMS
33%
Poorly correlated
+1.22%
More

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with CMRX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then CMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
N/A
CMRX - QURE
52%
Loosely correlated
N/A
NAMS - QURE
52%
Loosely correlated
+2.86%
HOOK - QURE
44%
Loosely correlated
+4.00%
AXON - QURE
42%
Loosely correlated
+3.82%
ABSI - QURE
38%
Loosely correlated
-0.47%
More